Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts

Neurotherapeutics

Volumn 13, Issue 4, 2016, Pages 811-820

  Pennell, Page B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Breastfeeding; Epilepsy; Neuropsychiatric disorders; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LEVETIRACETAM; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ARTICLE; BREAST FEEDING; CLEFT LIP; CLEFT PALATE; CONGENITAL MALFORMATION; DISEASE CONTROL; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPILEPSY; HIGH RISK PREGNANCY; HUMAN; HYPOSPADIAS; LOW BIRTH WEIGHT; MATERNAL WELFARE; MONOTHERAPY; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SMALL FOR DATE INFANT; CHEMICALLY INDUCED; FEMALE; MENTAL DISEASE; PERSONALIZED MEDICINE; PREGNANCY COMPLICATIONS;

ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; NEURODEVELOPMENTAL DISORDERS; PRECISION MEDICINE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84981155248     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0464-0     Document Type: Article

References (57)

1. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1237-1246.
2. Adedinsewo DA, Thurman DJ, Luo YH, Williamson RS, Odewole OA, Oakley GP, Jr. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol 2013;97:403-408.
3. Bobo WV, Davis RL, Toh S, et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol 2012;26:578-588.
4. Harden CL, Hopp J, Ting TY, et al. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1229-1236.
5. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1247-1255.
6. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-1699.
7. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004;45:1463-1464.
8. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
9. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014;85:1029-1034.
10. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011;68:1275-1281.
11. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71:272-276.
12. Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.
13. Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ. The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014;130:234-238.
14. Hernandez-Diaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014;123:21-28.
15. US Food and Drug Administration. Safety Label Changes 2011. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm249643.htm. Accessed ??.
16. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400-405.
17. Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013;80:1565-1570.
18. Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology 2016;86:2251-2257.
19. Pennell PB, Klein AM, Browning N, et al. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav 2012;24:449-456.
20. MacDonald SC, Bateman BT, McElrath TF, Hernandez-Diaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurol 2015;72:981-988.
21. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013;12:244-252.
22. Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013;84:637-643.
23. Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-1703.
24. Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 2014;82:213-221.
25. Deshmukh U, Adams J, Macklin EA, et al. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol Teratol 2016;54:5-14.
26. US Food and Drug Administration. FDA Drug Safety Communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. Available at: http://www.fda.gov/drugs/drugsafety/ucm350684.htm. Accessed ??
27. European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls 2014 (updated November 21, 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/11/WC500177638.pdf. Accessed ??
28. Pennell PB MK, May RC, French J, et al.; MONEAD Investigator Group. Antiepileptic drug prescribing patterns in women with epilepsy during pregnancy: findings from the MONEAD study. 2015 American Epilepsy Society Annual Meeting; 20152015.
29. Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter Update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Neurology 2009;73:142-149.
30. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008;70:2130-2136.
31. Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:292-295.
32. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002;59:251-255.
33. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006;66:354-360.
34. Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013;54:1621-1627.
35. Polepally AR, Pennell PB, Brundage RC, et al. Model-based lamotrigine clearance changes during pregnancy: clinical implication. Ann Clin Transl Neurol 2014;1:99-106.
36. Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008;17:192-198.
37. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007;48:1111-1116.
38. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007;46:209-219.
39. Lopez-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav 2009;15:372-375.
40. Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav 2013;29:13-18.
41. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013;54:405-414.
42. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276.
43. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:142-149.
44. Johnson EL, Stowe ZN, Ritchie JC, et al. Carbamazepine clearance and seizure stability during pregnancy. Epilepsy Behav 2014;33:49-53.
45. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012;11:803-813.
46. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571.
47. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 2008;17:199-202.
48. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005;46:1414-1417.
49. Wegner I, Wilhelm AJ, Lambrechts DA, Sander JW, Lindhout D. Effect of oral contraceptives on lamotrigine levels depends on comedication. Acta Neurol Scand 2014;129:393-398.
50. Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009;73:1388-1393.
51. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009;72:911-914.
52. Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med 2009;4(Suppl. 1):S17-S30.
53. Figueiredo B, Dias CC, Brandao S, Canario C, Nunes-Costa R. Breastfeeding and postpartum depression: state of the art review. J Pediatr (Rio J) 2013;89:332-338.
54. Bernard JY, De Agostini M, Forhan A, et al. Breastfeeding duration and cognitive development at 2 and 3 years of age in the EDEN mother-child cohort. J Pediatr 2013;163:36-42.
55. Belfort MB, Rifas-Shiman SL, Kleinman KP, et al. Infant feeding and childhood cognition at ages 3 and 7 years: Effects of breastfeeding duration and exclusivity. JAMA Pediatr 2013;167:836-844.
56. Julvez J, Guxens M, Carsin AE, et al. A cohort study on full breastfeeding and child neuropsychological development: the role of maternal social, psychological, and nutritional factors. Dev Med Child Neurol 2014;56:148-156.
57. Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 2014;168:729-736.